Dinoprostone
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Dinoprostone
| |
| Systematic (IUPAC) name | |
| 7-[3-hydroxy-2-(3-hydroxyoct-1-enyl)- 5-oxo-cyclopentyl] hept-5-enoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | G02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H32O5 |
| Mol. mass | 352.465 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Dinoprostone | |
|
Articles | |
|---|---|
|
Most recent articles on Dinoprostone Most cited articles on Dinoprostone | |
|
Media | |
|
Powerpoint slides on Dinoprostone | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Dinoprostone at Clinical Trials.gov Clinical Trials on Dinoprostone at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Dinoprostone
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Dinoprostone Discussion groups on Dinoprostone Patient Handouts on Dinoprostone Directions to Hospitals Treating Dinoprostone Risk calculators and risk factors for Dinoprostone
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Dinoprostone | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
In medicine, dinoprostone, is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour and also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts.
It is sold under the trade name of Cervidil (by Forest Laboratories Inc.), Prostin E2 (by Pfizer Inc.) and Propess (by Ferring Pharmaceuticals), as a vaginal suppository, to prepare the cervix for labour; it is used to induce labour.
The chemical name is (5Z,11(alpha),13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1-oic acid.
Like other prostaglandins, dinoprostone can be used as an abortifacient.
External links
- Dinoprostone - medlineplus.org
- Cervidil - Forest Laboratories, Inc. (the manufacturer of Cervidil).
- Prostin E2 - pfizer.com
- Cervidil/Prostin E2 - RxList.com
- What is Cervidil? - birthingnaturally.net.
- Cervidil/Prostin E2 - drugs.com
Eicosanoids: prostaglandins | |
|---|---|
| Endogenous/series 2 | D2 - E2 (Dinoprostone) - F2 (Dinoprost) - H2 - I2 (Prostacyclin) |
| Prostaglandin analogues | E: Alprostadil - Enprostil - Misoprostol
F: Bimatoprost - Carboprost - Latanoprost - Travoprost I: Beraprost - Iloprost - Treprostinil |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
